Stock Analysis on Net
Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

Common-Size Income Statement
Quarterly Data

Abbott Laboratories, common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net sales 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost of products sold, excluding amortization of intangible assets -44.49 -45.40 -44.93 -44.43 -45.52 -44.47 -43.82 -41.93 -41.56 -40.47 -48.39 -42.09 -41.99 -44.80 -44.53 -42.47 -41.30 -41.58 -41.10 -41.94
Amortization of intangible assets -4.70 -4.89 -4.99 -5.04 -4.92 -4.78 -4.50 -4.30 -4.48 -4.76 -4.93 -4.87 -4.75 -5.76 -7.55 -7.26 -5.81 -5.99 -6.05 -6.45
Gross profit 50.82% 49.71% 50.08% 50.53% 49.57% 50.75% 51.67% 53.77% 53.96% 54.77% 46.68% 53.04% 53.27% 49.44% 47.93% 50.27% 52.89% 52.43% 52.85% 51.61%
Research and development -6.84 -6.63 -7.17 -6.71 -7.18 -7.51 -6.08 -5.86 -6.64 -6.15 -6.40 -6.25 -6.52 -6.55 -7.70 -7.48 -7.16 -7.38 -7.23 -8.92
Selling, general and administrative -26.60 -26.85 -27.46 -28.34 -29.46 -26.23 -24.49 -23.43 -26.58 -25.32 -26.67 -26.62 -24.02 -26.00 -31.06 -32.98 -29.02 -30.21 -30.51 -32.89
Operating earnings 17.38% 16.24% 15.45% 15.48% 12.92% 17.00% 21.11% 24.48% 20.74% 23.30% 13.62% 20.17% 22.73% 16.89% 9.17% 9.81% 16.71% 14.83% 15.11% 9.81%
Interest expense -1.55 -1.64 -1.59 -1.57 -1.53 -1.35 -1.17 -1.10 -1.14 -1.22 -1.31 -1.29 -1.27 -1.55 -1.83 -1.80 -1.97 -2.07 -2.11 -2.27
Interest income 0.87 0.96 0.98 1.04 0.87 0.53 0.23 0.12 0.10 0.09 0.11 0.11 0.08 0.11 0.12 0.23 0.30 0.30 0.28 0.31
Net foreign exchange gain (loss) -0.23 0.10 -0.21 -0.06 0.14 -0.18 0.00 0.03 0.05 -0.04 0.00 -0.03 0.05 0.08 0.01 -0.06 0.02 -0.09 0.05 -0.08
Net loss on extinguishment of debt 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.76 0.00 0.00 0.00
Other income (expense), net 1.06 0.82 1.76 1.14 0.67 0.89 0.73 0.66 0.55 0.68 0.77 0.58 0.73 0.52 -0.30 0.01 0.61 0.68 0.48 0.62
Earnings from continuing operations before taxes 17.53% 16.47% 16.40% 16.03% 13.08% 16.89% 20.89% 24.18% 20.29% 22.81% 13.19% 19.54% 22.32% 16.05% 7.18% 8.19% 14.91% 13.66% 13.81% 8.39%
Taxes on earnings from continuing operations -1.96 -2.32 -2.62 -2.50 -2.84 -3.10 -2.97 -3.61 -2.95 -3.60 -1.56 -2.39 -2.15 -2.13 0.15 -1.15 -2.30 -1.77 -1.20 0.53
Earnings from continuing operations 15.56% 14.16% 13.78% 13.52% 10.24% 13.78% 17.93% 20.57% 17.34% 19.22% 11.63% 17.15% 20.17% 13.92% 7.33% 7.04% 12.62% 11.89% 12.61% 8.92%
Net earnings from discontinued operations, net of tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.26 0.00 0.00 0.00 0.00
Net earnings 15.56% 14.16% 13.78% 13.52% 10.24% 13.78% 17.93% 20.57% 17.34% 19.22% 11.63% 17.15% 20.20% 13.92% 7.33% 7.30% 12.62% 11.89% 12.61% 8.92%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Operating earnings The net result for the period of deducting operating expenses from operating revenues. Abbott Laboratories operating earnings as a percentage of net sales increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Earnings from continuing operations before taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Abbott Laboratories earnings from continuing operations before taxes as a percentage of net sales increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Net earnings The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Abbott Laboratories net earnings as a percentage of net sales increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.